The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase III study comparing 2-weekly docetaxel, cisplatin and 5-FU (bDCF) with cisplatin and 5-FU (CF) in patients with metastatic or recurrent esophageal cancer: JCOG1314 (MIRACLE).
 
Takahiro Tsushima
Honoraria - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Shuichi Hironaka
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Hutchison MediPharma (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yasuhiro Tsubosa
No Relationships to Disclose
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Motoo Nomura
Honoraria - Bristol-MyersSquibbK.K.; MSD; ONOPHARMACEUTICALCO.,LTD.
 
Hiroki Hara
Honoraria - Asahi Kasei; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; MSD; Ono Pharmaceutical
Research Funding - ALX Oncology (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Janssen Oncology (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yuko Kitagawa
Honoraria - Asahi Kasei; ASKA Pharmaceutical Co., Ltd.; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Foundation for Innovative Drug Discovery Science; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED; EA Pharma; Ethicon; Intuitive Surgical; Kaken Pharmaceutical; Miyarisan pharmaceutical; MSD K.K.; Nippon Covidien; Nippon Kayaku; Olympus; Ono Pharmaceutical; Otsuka; Shionogi; Smith & Nephew; Sysmex; Taiho Pharmaceutical; Toray Industries
Consulting or Advisory Role - Bristol-Myers Squibb K.K.; Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); Eisai (Inst); Kaken Pharmaceutical (Inst); Kowa (Inst); Kyouwa Hakkou Kirin Co., Ltd. (Inst); Nippon Covidien (Inst); Otsuka (Inst); Otsuka (Inst); Sumitomo Pharma Co., Ltd. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); TSUMURA & CO. (Inst)
 
Kazuo Koyanagi
No Relationships to Disclose
 
Takeshi Kajiwara
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Taiho Pharmaceutical
 
Naoki Takegawa
No Relationships to Disclose
 
Hisahiro Matsubara
No Relationships to Disclose
 
Hideo Baba
Honoraria - Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); AstraZeneca Japan (Inst); bitBiome (Inst); Chugai Pharma (Inst); Eisai (Inst); Johnson & Johnson K.K. (Inst); Lilly Japan (Inst); Shin Nippon Biomedical (Inst); Taiho Pharmaceutical (Inst)
 
Masaru Morita
No Relationships to Disclose
 
Toru Masuzawa
No Relationships to Disclose
 
Hiroko Hasegawa
No Relationships to Disclose
 
Takashi Kojima
Honoraria - Oncolys BioPharma; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; BMS; Merck; MSD
Research Funding - Astellas Amgen BioPharama (Inst); BMS (Inst); Chugai Pharma (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Parexel (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Ryunosuke Machida
No Relationships to Disclose
 
Keita Sasaki
No Relationships to Disclose
 
Hiroya Takeuchi
Honoraria - Abbott Japan; Bristol-Myers Squibb Japan; Daiichi Sankyo/Astra Zeneca; EA Pharma; Hisamitsu Pharmaceutical; Intuitive Surgical; Johnson & Johnson/MedTech; Kaken Pharmaceutical; Medicon; Medtronic; Miyarisan pharmaceutical; MSD K.K; Nichiiko K.K.; Ono Pharmaceutical; Otsuka; Otsuka; Taiho Pharmaceutical; Tsumura & Co.
Research Funding - Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Johnson & Johnson/MedTech; Kaken Pharmaceutical; Kyowa Hakko Kirin K. K.; Lilly Japan; Otsuka; Taiho Pharmaceutical
 
Shigenori Kadowaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Merck KGaA; MSD; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); Nobelpharma (Inst); Ono Pharmaceutical (Inst)